Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.46 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.46 |
| ▸ | ATM | Q13315 | 1/20 | 0.44 |
| ▸ | ACACB | O00763 | 11/20 | 0.40 |
| ▸ | ACACA | Q13085 | 5/20 | 0.40 |
| ▸ | ITGB3 | P05106 | 1/20 | 0.40 |
| ▸ | ITGA2B | P08514 | 1/20 | 0.40 |
| ▸ | PCNA | P12004 | 1/20 | 0.39 |
| ▸ | POLB | P06746 | 1/20 | 0.38 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.38 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.38 |
| ▸ | GRN | P28799 | 1/20 | 0.37 |
| ▸ | SORT1 | Q99523 | 1/20 | 0.37 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6478695 | 1.00 | KDM4E (0.48) | KDM4EALDH1A1L3MBTL1ATMACACB | |
| SCHEMBL6488460 | 0.86 | GRN (0.46) | ATMACACBITGB3ITGA2BPCNA | |
| SCHEMBL6488465 | 0.86 | GRN (0.46) | ATMACACBITGB3ITGA2BPCNA | |
| SCHEMBL6478754 | 0.85 | LMNA (0.47) | ATMACACBACACAITGB3ITGA2B | |
| SCHEMBL6478751 | 0.85 | LMNA (0.47) | ATMACACBACACAITGB3ITGA2B | |
| SCHEMBL6492386 | 0.82 | KMT2A (0.46) | KDM4EATMITGB3ITGA2BPCNA | |
| SCHEMBL6492391 | 0.82 | KMT2A (0.46) | KDM4EATMITGB3ITGA2BPCNA | |
| SCHEMBL6488494 | 0.79 | ATM (0.49) | ATMITGB3ITGA2BPCNAHDAC8 | |
| SCHEMBL7688482 | 0.79 | ATM (0.49) | ATMITGB3ITGA2BPCNAHDAC8 | |
| SCHEMBL6479393 | 0.78 | ATM (0.45) | ATMITGB3ITGA2BPCNAHDAC8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050043358-A1 | Aminoalcohol derivatives and their use as beta 3 adrenergic agonists | FUJISAWA PHARMACEUTICAL CO. LTD. (JP) | 2005-02-24 | — | — | US | disclosed |
| US-20020143034-A1 | Aminoalcohol derivatives and their use as beta 3 adrenergic agonists | FUJISAWA PHARMACEUTICAL CO. LTD. (JP) | 2002-10-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020143034-A1 | Aminoalcohol derivatives and their use as beta 3 adrenergic agonists | ADRB1, ADRB2, ADRB3 | KDM4E 3411/4885ALDH1A1 275/4885L3MBTL1 2659/4885 |
| US-20050043358-A1 | Aminoalcohol derivatives and their use as beta 3 adrenergic agonists | ADRB2, ADRB1, ADRB3 | KDM4E 3442/4885ALDH1A1 578/4885L3MBTL1 2835/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.